Suggested Remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy .
 
Status In progress
Process STA 2018
ID number 1518

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 August 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy. Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course.
21 May 2019 - 19 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 December 2017 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance